No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ME240621P1000
- 0.28
- 0.000.00%
15min DelayTrading May 30 10:08 ET
0.00High0.00Low
0.00Open0.28Pre Close0 Volume22 Open Interest1.00Strike Price0.00Turnover0.00%IV30.10%PremiumJun 21, 2024Expiry Date0.45Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.98Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Express News | 23andMe Holdings: 23Me-00610 monotherapy continues to demonstrate acceptable safety and tolerability.
Express News | Tumor Cd200 is becoming a potential biomarker associated with the efficacy of the single therapy 23Me-00610 in 23Andme Holding Co.
Express News | 23Andme Holding Co.: Tumor Cd200 Is Emerging as a Potential Biomarker Associated With 23Me-00610 Monotherapy Efficacy
Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Continues to Demonstrate Acceptable Safety and Tolerability
Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Demonstrates Preliminary Evidence of Clinical Benefit, Including One Confirmed Partial Response
Express News | 23Andme Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23Me-00610, Targeting Cd200R1, at the 2024 Asco Annual Meeting